CART cell and hematopoietic stem cell combined transplantation method and system
Through the combined transplantation method of CART cells and hematopoietic stem cells, combined with intelligent system design and gene editing technology, the lack of targets and immunosuppression of CART cell therapy in solid tumor treatment has been solved, achieving more efficient and safer tumor treatment effects .
Patent Information
- Application Number
- CN202410918677.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-10
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing CART cell therapies face problems such as lack of targets, difficulty in cell transport, immunosuppression of tumor microenvironment and endogenous T cell inhibition signal in solid tumor treatment, resulting in limited efficacy and safety.
The combined transplantation method of CART cells and hematopoietic stem cells is adopted, and a reasonable joint transplantation plan, gene editing, multi-level immune regulation and personalized treatment plan is designed through an intelligent system to ensure that the cells work together in the body, enhance the anti-tumor effect and reduce side effects.
The effective synergy between CART cells and hematopoietic stem cells in the body is achieved, which significantly improves the effect of tumor treatment, ensures the targeted and safe treatment, reduces the risk of side effects, and improves the controllability and prognosis of treatment.
Smart Images

Figure CN118888084A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to but is not limited to the field of tumor immunotherapy technology, and in particular relates to a method and system for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy. Background Art
[0002] Currently, CART cell therapy faces many challenges in the field of solid tumor treatment, such as lack of effective targets, difficulty in CART cell transport and infiltration, immunosuppression of the tumor microenvironment, and endogenous T cell inhibitory signals. These problems limit the efficacy and safety of CART cells in the treatment of solid tumors. The present invention successfully solves these prior art problems through combined transplantation scheme design, anti-tumor gene modification, multi-level immune regulation and personalized treatment scheme.
[0003] In view of the above analysis, the technical problems that need to be solved urgently in the prior art are:
[0004] (1) Coordination of combined transplantation: How to achieve effective combined transplantation of CART cells and hematopoietic stem cells in vivo and ensure that the two can work synergistically;
[0005] (2) Enhancement of anti-tumor effects: How to improve the anti-tumor effects of CART cells and hematopoietic stem cells after combined transplantation to achieve better therapeutic effects;
[0006] (3) Side effects and safety: Avoid possible side effects of combined transplantation and ensure the safety and controllability of treatment. Summary of the invention
[0007] In response to the problems existing in the prior art, the present invention provides a method and system for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy.
[0008] The present invention is implemented as follows: an intelligent system for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy, comprising:
[0009] The data collection and preprocessing module is used to collect the patient's clinical data, including tumor type, disease progression, immune status, etc., using the electronic health record system, and process the data using machine learning and data analysis tools to determine the optimal timing and ratio of combined transplantation;
[0010] The model building and verification module is used to use bioinformatics and systems biology tools to establish mathematical models based on biology and immunology, simulate the dynamic behavior of CART cells and hematopoietic stem cells in the body, and use optimization algorithms to simulate the effects of different transplantation schemes and select the optimal scheme;
[0011] The clinical trial design module is used to design and implement randomized controlled clinical trials based on the model and algorithm results to verify the optimal transplantation timing and ratio;
[0012] The gene editing module is used to use CRISPR / Cas9 technology to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes, and to screen and verify the effects of gene modification through flow cytometry and molecular biology methods.
[0013] Furthermore, it also includes:
[0014] Multi-level immune regulation module, which is used to adopt multiple immune regulation methods, such as immune checkpoint inhibitors, cytokine therapy, etc., to enhance the anti-tumor effect of combined transplantation while reducing side effects;
[0015] The personalized treatment plan module is used to develop personalized treatment plans based on the patient's specific situation using artificial intelligence platforms and bioinformatics tools, including the selection and transformation strategies of CART cells and hematopoietic stem cells to ensure the targetedness and effectiveness of the treatment;
[0016] Visual display module, which is used to present data analysis results, model simulation results and personalized treatment plans to clinicians in an intuitive and easy-to-understand way through charts, animations, etc., to support clinical decision-making;
[0017] The dynamic adjustment module is used to dynamically adjust the treatment plan based on real-time monitoring data and patient feedback information using a reinforcement learning algorithm to ensure the optimal effect of the treatment plan.
[0018] The present invention also provides a method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy, and a method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy, which specifically comprises:
[0019] S1: Design of combined transplantation program: formulate a reasonable combined transplantation program, determine the optimal transplantation time and ratio of CART cells and hematopoietic stem cells, and ensure the effective synergy of the two in vivo;
[0020] S2: Anti-tumor gene modification: Genetically modify CART cells and hematopoietic stem cells to express genes with stronger anti-tumor effects, thereby enhancing their anti-tumor ability in vivo;
[0021] S3: Multi-level immune regulation: Use a variety of immune regulation methods, such as immune checkpoint inhibitors, cytokine therapy, etc., to enhance the anti-tumor effect of combined transplantation while reducing side effects;
[0022] S4: Personalized treatment plan: Develop a personalized treatment plan based on the patient's specific situation, including the selection and transformation strategies of CART cells and hematopoietic stem cells, to ensure the targetedness and effectiveness of the treatment.
[0023] Further, the S1 comprises the following steps:
[0024] (1) Data collection and preprocessing: Use the electronic health record system to collect the patient's clinical data, including tumor type, disease progression, immune status, etc., and use machine learning and data analysis tools to process the data to determine the optimal timing and ratio of combined transplantation;
[0025] (2) Model construction and validation: Using bioinformatics and systems biology tools, we established mathematical models based on biology and immunology to simulate the dynamic behavior of CART cells and hematopoietic stem cells in vivo. We also used optimization algorithms to simulate the effects of different transplantation schemes and select the optimal scheme.
[0026] (3) Clinical trial implementation: Based on the model and algorithm results, design and implement randomized controlled clinical trials to verify the optimal transplant timing and ratio.
[0027] Further, the S2 comprises the following steps:
[0028] (1) Gene editing: Use CRISPR / Cas9 to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes. The anti-tumor gene targets include PD1, CTLA4, etc.
[0029] (2) Vector construction: construct vectors containing anti-tumor genes, such as adenovirus, lentivirus, etc., and perform viral transfection;
[0030] (3) Screening and verification: Screen and verify the effects of gene modification through flow cytometry and molecular biology methods.
[0031] Further, the S3 comprises the following steps:
[0032] (1) Drug screening: Establish an immune regulatory drug library, including immune checkpoint inhibitors, cytokines, etc., and use a high-throughput screening platform to screen immune regulatory drugs;
[0033] (2) Combination therapy: Design and test combination therapy regimens, evaluate their anti-tumor effects and side effects, and adjust the regimens individually based on the patient's immune status;
[0034] (3) Clinical trials: Verify the safety and effectiveness of combination treatments in clinical trials.
[0035] Further, the S4 comprises the following steps:
[0036] (1) Data integration: using bioinformatics tools to integrate patient genome, epigenome, transcriptome, and proteome data;
[0037] (2) Analysis and modeling: Use artificial intelligence platforms to analyze data and build personalized treatment models;
[0038] (3) Program implementation: Based on the model results, design and implement a personalized CART cell and hematopoietic stem cell combined transplantation program.
[0039] Another object of the present invention is to provide a CART cell and hematopoietic stem cell combined transplantation system for tumor immunotherapy, comprising:
[0040] The program design module is used to design the optimal combined transplantation program;
[0041] The anti-tumor gene modification module is used to genetically modify selected cells to express genes with stronger anti-tumor effects;
[0042] Multi-level immune regulation module, which is used to adopt multiple immune regulation methods to enhance the anti-tumor effect of combined transplantation while reducing side effects;
[0043] The personalized treatment module is used to develop personalized treatment plans based on the patient's specific conditions.
[0044] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:
[0045] First, the present invention can optimize the design of the combined transplantation scheme: the combined transplantation scheme system designed by the present invention can accurately determine the optimal transplantation time and ratio of CART cells and hematopoietic stem cells according to the specific conditions of the patient and the characteristics of the tumor. This optimization not only improves the synergy of the two cells in the body, but also ensures the pertinence and effectiveness of the treatment, significantly improving the treatment effect.
[0046] The present invention can achieve precision in anti-tumor gene modification: by using advanced gene editing technology, the present invention can accurately modify CART cells and hematopoietic stem cells to express genes with stronger anti-tumor effects. This precision modification not only enhances the anti-tumor ability of cells, but also reduces the risk of off-target effects and side effects, providing strong support for the application of CART cell therapy in the treatment of solid tumors.
[0047] The present invention can achieve multi-level immune regulation and personalized treatment plans: The present invention uses multi-level immune regulation strategies, including immune checkpoint inhibitors and cytokine therapy, to effectively enhance the anti-tumor effects of CART cells and hematopoietic stem cells and reduce immune-related side effects during treatment. At the same time, by developing a personalized treatment plan system, targeted treatment plans can be formulated according to the specific conditions of the patient, ensuring the pertinence and effectiveness of the treatment, and providing patients with safer and more effective CART cell therapy.
[0048] Second, the present invention solves several key problems in the prior art, especially in the monitoring and management of combined transplantation of CART cells and hematopoietic stem cells in tumor immunotherapy. Traditional immunotherapy methods mainly rely on clinical experience and regular laboratory tests, and it is difficult to obtain the dynamic changes of immune cells in patients in real time, resulting in delayed adjustment of treatment plans, affecting the treatment effect and patient prognosis. In addition, the existing methods lack comprehensive analysis of multi-omics data, and cannot deeply analyze the dynamic changes of CART cells and hematopoietic stem cells in the process of combined transplantation and their contribution to anti-tumor effects, thereby limiting the formulation of personalized treatment plans.
[0049] The present invention integrates a number of advanced technologies such as data collection and preprocessing, model construction and verification, gene editing, and multi-level immune regulation by introducing an intelligent system, which significantly improves the real-time and accuracy of immunotherapy monitoring. The electronic health record system and machine learning tools are used to collect and process the patient's clinical data, and a mathematical model is established through bioinformatics and systems biology tools to simulate the dynamic behavior of CART cells and hematopoietic stem cells in the body. The optimization algorithm is used to simulate the effects under different transplantation schemes and select the optimal scheme. At the same time, CART cells and hematopoietic stem cells are transformed by CRISPR / Cas9 gene editing technology to enhance their anti-tumor ability, and a high-throughput screening platform is used to screen the most effective combination of immunomodulatory drugs to improve the therapeutic effect.
[0050] Through the synergy of the data integration module and the data analysis module, the present invention can comprehensively analyze multi-source data, and use machine learning and artificial intelligence algorithms to deeply mine the changing trends and anti-tumor effects of CART cells and hematopoietic stem cells. This not only improves the accuracy and reliability of data analysis, but also provides a scientific basis for the formulation of personalized treatment plans. In particular, through the intelligent recommendation and dynamic adjustment modules, the system can automatically generate and adjust the optimal treatment plan based on real-time monitoring data and patient feedback information, covering the selection of CART cells and hematopoietic stem cells, transformation strategies, and the combination and dosage of immunomodulatory drugs to ensure the personalization and accuracy of the treatment plan.
[0051] In summary, the present invention has made significant technological progress in the field of tumor immunotherapy. It not only solves the problems of real-time monitoring and comprehensive data analysis in the existing technology, but also optimizes and dynamically adjusts the treatment plan through the application of intelligent algorithms and models, thereby improving the treatment effect and patient prognosis. The innovative application of this system is expected to provide strong technical support for clinical treatment and promote the development of the field of tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 It is a flow chart of a combined transplantation method of CART cells and hematopoietic stem cells for tumor immunotherapy provided by an embodiment of the present invention;
[0053] Figure 2 This is a module diagram of a CART cell and hematopoietic stem cell combined transplantation system for tumor immunotherapy provided by an embodiment of the present invention.
[0054] Figure 3 The comparison of the effects of the traditional method and the method of the present invention in real-time monitoring of immunotherapy is shown. The red curve represents the traditional method, and the blue curve represents the method of the present invention. The method of the present invention realizes real-time and accurate monitoring of the dynamic changes of CART cells and hematopoietic stem cells by introducing an intelligent system, significantly improving the monitoring accuracy.
[0055] Figure 4 The comparison of the effects of the traditional method and the method of the present invention in optimizing the treatment plan is demonstrated. DETAILED DESCRIPTION
[0056] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0057] like Figure 1 As shown, an embodiment of the present invention provides a method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy, the method specifically comprising:
[0058] S1: Design of combined transplantation program: formulate a reasonable combined transplantation program, determine the optimal transplantation time and ratio of CART cells and hematopoietic stem cells, and ensure the effective synergy of the two in vivo;
[0059] S2: Anti-tumor gene modification: Genetically modify CART cells and hematopoietic stem cells to express genes with stronger anti-tumor effects, thereby enhancing their anti-tumor ability in vivo;
[0060] S3: Multi-level immune regulation: Use a variety of immune regulation methods, such as immune checkpoint inhibitors, cytokine therapy, etc., to enhance the anti-tumor effect of combined transplantation while reducing side effects;
[0061] S4: Personalized treatment plan: Develop a personalized treatment plan based on the patient's specific situation, including the selection and transformation strategies of CART cells and hematopoietic stem cells, to ensure the targetedness and effectiveness of the treatment.
[0062] The system first classifies the patient's clinical data through a machine learning-based classification algorithm to identify different tumor types and immune states. Classification algorithms include decision trees, support vector machines, and random forests. These algorithms use a large number of training data sets to optimize model parameters to accurately classify the patient's immune status and the best time for transplantation. For example, decision trees decompose data layer by layer by constructing decision nodes and leaf nodes, support vector machines classify by finding the best hyperplane, and random forests improve classification accuracy and robustness by integrating multiple decision trees.
[0063] Before implementing the classification algorithm, the patient's clinical data must first be preprocessed. This includes steps such as data cleaning, normalization, and feature extraction. Data cleaning is used to remove missing values and outliers, normalization standardizes the data to a uniform scale, and feature extraction improves the performance of the model by selecting the most representative features. The preprocessed data can better reflect the patient's actual situation, thereby improving the accuracy of the classification algorithm.
[0064] In order to predict the changing trends of the number, proportion and activity parameters of CART cells and hematopoietic stem cells after combined transplantation, the system uses prediction models based on artificial intelligence. These models include neural networks, long short-term memory networks (LSTM) and recurrent neural networks (RNN). Neural networks capture complex nonlinear relationships through the connection of multiple layers of neurons; LSTM can effectively capture long-range dependencies in time series through its special gating mechanism; RNN is good at processing sequence data through its cyclic structure.
[0065] When building a prediction model, you first need to use a large amount of historical data to train the model. The historical data includes information such as the patient's immune status, the number and proportion of CART cells and hematopoietic stem cells, and the treatment effect. By training on these data, the model can learn the behavior patterns of CART cells and hematopoietic stem cells under different conditions and predict their future changing trends. During the training process, the model's hyperparameters and structure are adjusted to improve the prediction accuracy of the model.
[0066] In order to ensure the accuracy of the prediction model, the system introduces a real-time monitoring and dynamic adjustment mechanism. Through molecular imaging and biomarker monitoring technology, the number, proportion and activity parameters of CART cells and hematopoietic stem cells in the patient's body are obtained in real time. The real-time monitoring data is input into the prediction model, and the parameters and structure of the model are adjusted according to the latest data to improve the real-time prediction ability of the model. Through dynamic adjustment, the model can more accurately reflect the patient's immune reconstitution status and evaluate the treatment effect and progress.
[0067] With the support of classification algorithms and prediction models, the system provides personalized treatment plans by comprehensively optimizing the parameters and strategies of each module. Combined with the patient's clinical data and real-time monitoring data, the system can accurately predict the performance of CART cells and hematopoietic stem cells after combined transplantation, and adjust the treatment plan accordingly to optimize the treatment effect. By comparing the model prediction results with the actual treatment results, the performance of the model is evaluated, and the model and optimization strategy are further improved to improve the overall treatment effect and reliability of the system.
[0068] The S1 comprises the following steps:
[0069] (1) Data collection and preprocessing: Use the electronic health record system to collect the patient's clinical data, including tumor type, disease progression, immune status, etc., and use machine learning and data analysis tools to process the data to determine the optimal timing and ratio of combined transplantation;
[0070] (2) Model construction and validation: Using bioinformatics and systems biology tools, we established mathematical models based on biology and immunology to simulate the dynamic behavior of CART cells and hematopoietic stem cells in vivo. We also used optimization algorithms to simulate the effects of different transplantation schemes and select the optimal scheme.
[0071] (3) Clinical trial implementation: Based on the model and algorithm results, design and implement randomized controlled clinical trials to verify the optimal transplant timing and ratio.
[0072] The S2 comprises the following steps:
[0073] (1) Gene editing: Use CRISPR / Cas9 to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes. The anti-tumor gene targets include PD1, CTLA4, etc.
[0074] (2) Vector construction: construct vectors containing anti-tumor genes, such as adenovirus, lentivirus, etc., and perform viral transfection;
[0075] (3) Screening and verification: Screen and verify the effects of gene modification through flow cytometry and molecular biology methods.
[0076] The S3 comprises the following steps:
[0077] (1) Drug screening: Establish an immune regulatory drug library, including immune checkpoint inhibitors, cytokines, etc., and use a high-throughput screening platform to screen immune regulatory drugs;
[0078] (2) Combination therapy: Design and test combination therapy regimens, evaluate their anti-tumor effects and side effects, and adjust the regimens individually based on the patient's immune status;
[0079] (3) Clinical trials: Verify the safety and effectiveness of combination treatments in clinical trials.
[0080] The S4 comprises the following steps:
[0081] (1) Data integration: using bioinformatics tools to integrate patient genome, epigenome, transcriptome, and proteome data;
[0082] (2) Analysis and modeling: Use artificial intelligence platforms to analyze data and build personalized treatment models;
[0083] (3) Program implementation: Based on the model results, design and implement a personalized CART cell and hematopoietic stem cell combined transplantation program.
[0084] like Figure 2 As shown, the CART cell and hematopoietic stem cell combined transplantation system for tumor immunotherapy provided by the embodiment of the present invention includes:
[0085] The program design module is used to design the optimal combined transplantation program;
[0086] The anti-tumor gene modification module is used to genetically modify selected cells to express genes with stronger anti-tumor effects;
[0087] Multi-level immune regulation module, which is used to adopt multiple immune regulation methods to enhance the anti-tumor effect of combined transplantation while reducing side effects;
[0088] The personalized treatment module is used to develop personalized treatment plans based on the patient's specific conditions.
[0089] Example 1: Personalized combined transplantation therapy for leukemia patients
[0090] System Design:
[0091] 1. Clinical data collection and analysis:
[0092] Data collection: Clinical data of leukemia patients were collected, including medical history, gene mutation type, disease progression, and immune status.
[0093] Analytical tools: Use machine learning tools to process data and determine the optimal timing and ratio of CART cell and hematopoietic stem cell transplantation.
[0094] 2. Computational model:
[0095] Biological model: Establish a mathematical model specific to leukemia pathology to simulate the dynamic behavior of CART cells and hematopoietic stem cells in the patient's body.
[0096] Optimization algorithm: Use the optimization algorithm to simulate the effects of different combined transplantation schemes and select the best one.
[0097] 3. Clinical trial design:
[0098] Randomized controlled trials: Design and implement randomized controlled clinical trials to verify the optimal timing and ratio of transplantation.
[0099] Implementation method:
[0100] 1. Data collection and preprocessing:
[0101] Clinical data of patients were collected using an electronic health record system.
[0102] Data standardization ensures consistency and integrity.
[0103] 2. Model construction and verification:
[0104] Use systems biology tools to construct and validate biological models specific to leukemia pathology.
[0105] Simulation and optimization algorithms were used to evaluate the effects of different combined transplantation schemes.
[0106] 3. Clinical trial implementation:
[0107] Based on the model and algorithm results, clinical trials are designed and verified.
[0108] Randomized controlled trials were performed to evaluate the efficacy and safety of combined transplantation regimens.
[0109] Example 2: Anti-tumor gene modification and multi-level immune regulation in patients with solid tumors
[0110] System Design:
[0111] 1. Gene Editing Platform:
[0112] Tool of choice: Gene editing using CRISPR / Cas9.
[0113] Gene target selection: Select anti-tumor gene targets, such as PD1, CTLA4, etc.
[0114] 2. Vector construction and transfection:
[0115] Vector selection: Use adenoviral vectors for gene transfection.
[0116] Transfection technology: Optimize gene transfection technology to ensure efficient transfection rate.
[0117] 3. Screening of immunomodulatory drugs:
[0118] Establishment of drug library: Establish a drug library including immune checkpoint inhibitors, cytokines, etc.
[0119] Drug screening platform: Use high-throughput screening platform to screen effective drug combinations.
[0120] Implementation method:
[0121] 1. Gene editing and vector construction:
[0122] CRISPR / Cas9 is used to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes.
[0123] An adenoviral vector containing an anti-tumor gene was constructed and viral transfection was performed.
[0124] 2.Drug screening and combination therapy:
[0125] Screen immune regulatory drugs through high-throughput screening platform.
[0126] Design and test combination treatments of CART cells, hematopoietic stem cells and immunomodulatory drugs.
[0127] 3. Clinical trials:
[0128] Verify the safety and effectiveness of combination treatments in clinical trials.
[0129] Adjust the treatment plan according to the patient's individual immune status to achieve personalized treatment.
[0130] Through these two specific examples, the application of CART cells and hematopoietic stem cell transplantation in the treatment of leukemia and solid tumors is demonstrated. Combining genetic modification and multi-level immune regulation strategies can effectively improve the treatment effect, reduce side effects, and ultimately achieve personalized treatment.
[0131] Comparison of real-time monitoring effects: Figure 3 The comparison of the effects of the traditional method and the method of the present invention in real-time monitoring of immunotherapy is shown. The red curve represents the traditional method, and the blue curve represents the method of the present invention. The method of the present invention realizes real-time and accurate monitoring of the dynamic changes of CART cells and hematopoietic stem cells by introducing an intelligent system, significantly improving the monitoring accuracy.
[0132] Comparison of treatment plan optimization effects: Figure 4 The comparison of the effects of the traditional method and the method of the present invention in optimizing the treatment plan is shown. The green curve represents the traditional method, and the purple curve represents the method of the present invention. The method of the present invention uses multi-omics analysis and an intelligent recommendation system to achieve personalized and dynamic adjustment of the treatment plan, greatly improving the treatment effect.
[0133] These graphs clearly show that the present invention has achieved significant technical progress in real-time monitoring and treatment plan optimization, and can provide more accurate and effective support for clinical treatment.
[0134] The following is a specific implementation scheme combining algorithms and programs:
[0135] 1. Data collection and preprocessing module
[0136] Step 1: Data Collection
[0137] -Use the electronic health record system (EHR) to collect patients' clinical data, including tumor type, disease progression, immune status, etc.
[0138] Step 2: Data Preprocessing
[0139] -Data cleaning, handling of missing values and outliers.
[0140] -Data standardization and normalization processing.
[0141] ```Python
[0142] import pandas as pd
[0143] from sklearn.preprocessing import StandardScaler
[0144] #Data Collection
[0145] ehr_data=pd.read_csv('ehr_data.csv')
[0146] #Data cleaning
[0147] ehr_data.dropna(inplace=True)
[0148] #Data Standardization
[0149] scaler = StandardScaler()
[0150] ehr_data_scaled=scaler.fit_transform(ehr_data)
[0151] ```
[0152] 2. Model building and verification module
[0153] Step 1: Feature Selection
[0154] -Use feature selection algorithms (such as LASSO, Random Forest Importance Score) to select key features.
[0155] Step 2: Mathematical model construction
[0156] -Use bioinformatics and systems biology tools to develop mathematical models based on biology and immunology.
[0157] Step 3: Model validation and optimization
[0158] -Use optimization algorithms (such as genetic algorithms and particle swarm optimization) to simulate the effects of different transplantation schemes and select the best one.
[0159] ```Python
[0160] from sklearn.ensemble import RandomForestClassifier
[0161] from sklearn.model_selection import train_test_split,GridSearchCV
[0162] from sklearn.metrics import classification_report
[0163] #Feature selection
[0164] X = ehr_data_scaled[:,:-1]
[0165] y = ehr_data_scaled[:,-1]
[0166] X_train,X_test,y_train,y_test=train_test_split(X,y,test_size=0.2,random_state=42)
[0167] clf=RandomForestClassifier()
[0168] param_grid={'n_estimators':[50,100,200],'max_depth':[10,20,None]}
[0169] grid_search=GridSearchCV(clf,param_grid,cv=5)
[0170] grid_search.fit(X_train,y_train)
[0171] #Model Validation
[0172] y_pred=grid_search.predict(X_test)
[0173] print(classification_report(y_test,y_pred))
[0174] #Mathematical model construction and optimization
[0175] #Here we need to write mathematical models and optimization algorithms based on specific biological and immunological theories```
[0176] 3. Gene Editing Module
[0177] Step 1: Gene Editing
[0178] -Use CRISPR / Cas9 to gene-edit CART cells and hematopoietic stem cells to express anti-tumor genes.
[0179] Step 2: Vector construction and transfection
[0180] -Construct viral vectors (such as adenovirus, lentivirus) containing anti-tumor genes and perform viral transfection.
[0181] Step 3: Screening and Verification
[0182] -Screen and verify the effects of gene modification by flow cytometry and molecular biology methods.
[0183] ```Python
[0184] #This involves laboratory operations, and the code implementation is only a simulation process defgene_editing(cells,target_gene):
[0185] #Gene editing using CRISPR / Cas9
[0186] edited_cells=cripsr_cas9_edit(cells,target_gene)
[0187] return edited_cells
[0188] defconstruct_viral_vector(gene):
[0189] #Build viral vector
[0190] viral_vector=construct_vector(gene)
[0191] return viral_vector
[0192] deftransfection(cells,viral_vector):
[0193] # Perform virus transfection
[0194] transformed_cells=transfect(cells,viral_vector)
[0195] return transfected_cells
[0196] defscreening_and_validation(cells):
[0197] #Screening and Verification
[0198] screened_cells=flow_cytometry_screening(cells)
[0199] validated_cells=molecular_biology_validation(screened_cells)
[0200] return validated_cells
[0201] #Example Process
[0202] cart_cells = ... # Initial CART cells
[0203] hematopoietic_cells = ... # Initial hematopoietic stem cells
[0204] target_gene = 'PD-1'
[0205] edited_cart_cells=gene_editing(cart_cells,target_gene)
[0206] edited_hematopoietic_cells=gene_editing(hematopoietic_cells,target_gene)
[0207] viral_vector=construct_viral_vector(target_gene)
[0208] transformed_cart_cells=transfection(edited_cart_cells,viral_vector)
[0209] transformed_hematopoietic_cells=transfection(edited_hematopoietic_cells,viral_vector)
[0210] final_cart_cells=screening_and_validation(transfected_cart_cells)
[0211] final_hematopoietic_cells=screening_and_validation(transfected_hematopoietic_cells)```
[0212] 4. Multi-level immune regulation module
[0213] Step 1: Data Analysis
[0214] - Analyze data from multiple immune-modulatory approaches, including immune checkpoint inhibitors and cytokine therapy.
[0215] Step 2: Optimize the model
[0216] -Use deep neural networks to process and analyze multidimensional data to generate optimal drug combination solutions.
[0217] ```Python
[0218] from keras.models import Sequential
[0219] from keras.layers import Dense
[0220] from keras.optimizers importAdam
[0221] #Data Preparation
[0222] immunotherapy_data=...#Multi-level immune regulation data
[0223] #Build a deep neural network model
[0224] model=Sequential()
[0225] model.add(Dense(64,input_dim=immunotherapy_data.shape[1],activation='relu'))
[0226] model.add(Dense(64,activation='relu'))
[0227] model.add(Dense(1,activation='linear'))
[0228] model.compile(optimizer=Adam(),loss='mean_squared_error')
[0229] #Model training
[0230] model.fit(immunotherapy_data,epochs=50,batch_size=32,validation_split=0.2)
[0231] #Generate the optimal drug combination solution
[0232] optimal_combination=model.predict(immunotherapy_data)
[0233] ```
[0234] 5. Personalized treatment plan module
[0235] Step 1: Data Analysis
[0236] - Analyze patient-specific conditions using artificial intelligence platforms and bioinformatics tools.
[0237] Step 2: Generate a personalized plan
[0238] - Based on the analysis results, develop personalized treatment plans, including the selection and transformation strategies of CART cells and hematopoietic stem cells.
[0239] ```Python
[0240] #Data Analysis
[0241] patient_data=...#patient's specific data
[0242] #Personalized treatment plan generation
[0243] defgenerate_personalized_treatment(patient_data):
[0244] #Analyze data using artificial intelligence platforms and bioinformatics tools
[0245] ai_analysis_result=ai_platform_analysis(patient_data)
[0246] bioinformatics_result=bioinformatics_tool(patient_data)
[0247] #Develop personalized solutions based on analysis results
[0248] personalized_treatment_plan=design_treatment_plan(ai_analysis_result,bioinformatics_result)
[0249] returnpersonalized_treatment_planpersonalized_treatment=generate_personalized_treatment(patient_data)```
[0250] 6. Dynamic adjustment module
[0251] Step 1: Real-time monitoring
[0252] -Analyze based on real-time monitoring data and patient feedback information.
[0253] Step 2: Dynamic Adjustment
[0254] -Use reinforcement learning algorithms to dynamically adjust treatment plans to ensure the optimal effect of the treatment plan.
[0255] ```Python
[0256] import gym
[0257] import numpy as np
[0258] from keras.models import Sequential
[0259] from keras.layers import Dense
[0260] from keras.optimizers importAdam
[0261] #Environment definition
[0262] class ImmuneTherapyEnv(gym.Env):
[0263] def __init__(self):
[0264] self.state = ...
[0265] self.action_space = ...
[0266] self.observation_space = ...
[0267] defstep(self,action): ...
[0269] return next_state,reward,done,{}
[0270] defreset(self):
[0271] self.state = ...
[0272] return self.state
[0273] #Build a reinforcement learning model
[0274] model=Sequential()
[0275] model.add(Dense(64,input_dim=env.observation_space.shape[0],activation='relu'))
[0276] model.add(Dense(64,activation='relu'))
[0277] model.add(Dense(env.action_space.n,activation='linear'))
[0278] model.compile(optimizer=Adam(),loss='mse')
[0279] #Reinforcement Learning Training
[0280] for episode in range(1000):
[0281] state = env.reset()
[0282] done=False
[0283] while not done:
[0284] action=np.argmax(model.predict(state))
[0285] next_state,reward,done,_=env.step(action)
[0286] model.fit(state,reward+0.95*np.max(model.predict(next_state)),epochs=1,verbose=0)
[0287] state = next_state
[0288] ```
[0289] The above implementation scheme demonstrates how to use specific programs to implement classification, prediction, optimization and dynamic adjustment algorithms based on machine learning and artificial intelligence to improve the effectiveness and efficiency of the combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy.
[0290] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.
Claims
1. An intelligent system for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy, characterized in that: include: The data collection and preprocessing module is used to collect the patient's clinical data, including tumor type, disease progression, and immune status, using the electronic health record system, and process the data using machine learning and data analysis tools to determine the optimal timing and ratio of combined transplantation; The model building and verification module is used to use bioinformatics and systems biology tools to establish mathematical models based on biology and immunology, simulate the dynamic behavior of CART cells and hematopoietic stem cells in the body, and use optimization algorithms to simulate the effects of different transplantation schemes and select the optimal scheme; The clinical trial design module is used to design and implement randomized controlled clinical trials based on the results of the model and algorithm to verify the optimal transplantation timing and ratio; The gene editing module is used to use CRISPR / Cas9 technology to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes, and to screen and verify the effects of gene modification through flow cytometry and molecular biology methods.
2. The intelligent system according to claim 1, characterized in that: Also includes: Multi-level immune regulation module, which is used to adopt multiple immune regulation methods, such as immune checkpoint inhibitors and cytokine therapy, to enhance the anti-tumor effect of combined transplantation while reducing side effects; The personalized treatment plan module is used to develop personalized treatment plans based on the patient's specific situation using artificial intelligence platforms and bioinformatics tools, including the selection and transformation strategies of CART cells and hematopoietic stem cells to ensure the targetedness and effectiveness of the treatment; Visual display module, which is used to present data analysis results, model simulation results and personalized treatment plans to clinicians in an intuitive and easy-to-understand way through charts and animations to support clinical decision-making; The dynamic adjustment module is used to dynamically adjust the treatment plan based on real-time monitoring data and patient feedback information using a reinforcement learning algorithm to ensure the optimal effect of the treatment plan.
3. The intelligent system according to claim 1, characterized in that: The model building and verification module further includes: A classification algorithm based on machine learning is used to classify the patient's clinical data to identify different tumor types and immune states. The classification algorithm includes but is not limited to decision trees, support vector machines, and random forests. The model parameters are optimized through training data sets to achieve accurate classification of the patient's immune status and optimal transplantation timing. The artificial intelligence-based prediction model is used to predict the changing trends of the number, proportion and activity parameters of CART cells and hematopoietic stem cells after combined transplantation, so as to evaluate the treatment effect and progress. The prediction model includes but is not limited to neural networks, long short-term memory networks (LSTM) and recurrent neural networks (RNN). Through training with historical data and model optimization, high-precision predictions of future immune reconstitution status are generated.
4. The intelligent system according to claim 1, characterized in that: The multi-level immune regulation module further comprises: A deep learning-based optimization model is used to analyze data from a variety of immune-modulating methods, including data from immune checkpoint inhibitors and cytokine therapy, to optimize the combination and dosage of immune-modulating drugs. The optimization model uses a deep neural network to process and analyze multidimensional data to generate an optimal drug combination plan; The dynamic adjustment algorithm based on reinforcement learning is used to dynamically adjust the combination and dosage of immunomodulatory drugs according to real-time monitoring data and patient feedback information to ensure the optimal effect of the treatment plan. The reinforcement learning algorithm improves the adaptability and accuracy of the treatment plan through continuous learning and optimization.
5. A combined transplantation method of CART cells and hematopoietic stem cells for tumor immunotherapy, characterized in that: The method specifically includes: S1: Design of combined transplantation program: formulate a reasonable combined transplantation program, determine the optimal transplantation time and ratio of CART cells and hematopoietic stem cells, and ensure the effective synergy of the two in vivo; S2: Anti-tumor gene modification: Genetically modify CART cells and hematopoietic stem cells to express genes with stronger anti-tumor effects, thereby enhancing their anti-tumor ability in vivo; S3: Multi-level immune regulation: Use multiple immune regulation methods to enhance the anti-tumor effect of combined transplantation while reducing side effects; S4: Personalized treatment plan: Develop a personalized treatment plan based on the patient's specific situation, including the selection and transformation strategies of CART cells and hematopoietic stem cells, to ensure the targetedness and effectiveness of the treatment.
6. The method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy according to claim 5, characterized in that: The S1 comprises the following steps: (1) Data collection and preprocessing: Use the electronic health record system to collect patients' clinical data, including tumor type, disease progression, and immune status. Use machine learning and data analysis tools to process the data and determine the optimal timing and ratio of combined transplantation. (2) Model construction and validation: Using bioinformatics and systems biology tools, we established mathematical models based on biology and immunology to simulate the dynamic behavior of CART cells and hematopoietic stem cells in vivo. We also used optimization algorithms to simulate the effects of different transplantation schemes and select the optimal scheme. (3) Clinical trial implementation: Based on the model and algorithm results, design and implement randomized controlled clinical trials to verify the optimal transplant timing and ratio.
7. The method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy according to claim 5, characterized in that: The S2 comprises the following steps: (1) Gene editing: Use CRISPR / Cas9 to edit the genes of CART cells and hematopoietic stem cells to express anti-tumor genes and select anti-tumor gene targets; (2) Vector construction: construct a vector containing an anti-tumor gene and perform viral transfection; (3) Screening and verification: Screen and verify the effects of gene modification through flow cytometry and molecular biology methods.
8. The method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy according to claim 5, characterized in that: The S3 comprises the following steps: (1) Drug screening: Establish an immune regulatory drug library, including immune checkpoint inhibitors and cytokines, and use a high-throughput screening platform to screen immune regulatory drugs; (2) Combination therapy: Design and test combination therapy regimens, evaluate their anti-tumor effects and side effects, and adjust the regimens individually based on the patient's immune status; (3) Clinical trials: Verify the safety and effectiveness of combination treatments in clinical trials.
9. The method for combined transplantation of CART cells and hematopoietic stem cells for tumor immunotherapy according to claim 5, characterized in that: The S4 comprises the following steps: (1) Data integration: using bioinformatics tools to integrate patient genome, epigenome, transcriptome, and proteome data; (2) Analysis and modeling: Use artificial intelligence platforms to analyze data and build personalized treatment models; (3) Program implementation: Based on the model results, design and implement a personalized CART cell and hematopoietic stem cell combined transplantation program.
